ADA and chronic myelogenous leukemia, BCR-ABL1 positive: Additionally, dCF alongside with 2′chloro-2′-deoxyadenosine (cladribine), an adenosine analog that also possesses ADA inhibitory properties [53] and similarly to 2′-deoxyadenosine could be incorporated into mitochondrial and nuclear DNA triggering apoptosis, have been used for the treatment of chronic myelogenous leukemia, cutaneous T-cell lymphoma and chronic lymphocytic leukemia [1], though high doses of dCF are characterized by a relatively high toxicity, especially for central nervous system, kidney and liver, which results from tight-binding interaction with ADA.